{"id":"NCT00823901","sponsor":"Massachusetts General Hospital","briefTitle":"Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea","officialTitle":"A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2009-02","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2009-01-16","resultsPosted":"2012-06-15","lastUpdate":"2012-06-25"},"enrollment":83,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rosacea"],"interventions":[{"type":"DRUG","name":"Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel","otherNames":["Ziana"]},{"type":"DRUG","name":"Placebo gel","otherNames":["placebo"]}],"arms":[{"label":"Clindamycin/Tretinoin Gel","type":"EXPERIMENTAL"},{"label":"Placebo gel","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel are effective and safe in the treatment of papulopustular rosacea.","primaryOutcome":{"measure":"Mean Change in Number of Inflammatory Lesions From Baseline to Week 12","timeFrame":"Baseline, week 12","effectByArm":[{"arm":"Clindamycin/Tretinoin Gel","deltaMin":0.83,"sd":10.84},{"arm":"Placebo","deltaMin":-3.13,"sd":13.28}],"pValues":[{"comp":"OG000 vs OG001","p":"0.15"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["15389184","15153893","11907512","8425809","10617662","22395584"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":43},"commonTop":["Worsening rosacea","Facial Dryness","Facial scaling","Facial redness","Facial itching"]}}